Cargando…
Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Centers for Disease Control and Prevention
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949847/ https://www.ncbi.nlm.nih.gov/pubmed/36795625 http://dx.doi.org/10.15585/mmwr.mm7207a3 |
| _version_ | 1784893036627492864 |
|---|---|
| author | Fleming-Dutra, Katherine E. Ciesla, Allison Avrich Roper, Lauren E. Smith, Zachary R. Miller, Joseph D. Accorsi, Emma K. Verani, Jennifer R. Shang, Nong Derado, Gordana Wiegand, Ryan E. Pilishvili, Tamara Britton, Amadea Link-Gelles, Ruth |
| author_facet | Fleming-Dutra, Katherine E. Ciesla, Allison Avrich Roper, Lauren E. Smith, Zachary R. Miller, Joseph D. Accorsi, Emma K. Verani, Jennifer R. Shang, Nong Derado, Gordana Wiegand, Ryan E. Pilishvili, Tamara Britton, Amadea Link-Gelles, Ruth |
| author_sort | Fleming-Dutra, Katherine E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9949847 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Centers for Disease Control and Prevention |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99498472023-02-24 Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 Fleming-Dutra, Katherine E. Ciesla, Allison Avrich Roper, Lauren E. Smith, Zachary R. Miller, Joseph D. Accorsi, Emma K. Verani, Jennifer R. Shang, Nong Derado, Gordana Wiegand, Ryan E. Pilishvili, Tamara Britton, Amadea Link-Gelles, Ruth MMWR Morb Mortal Wkly Rep Full Report Centers for Disease Control and Prevention 2023-02-17 /pmc/articles/PMC9949847/ /pubmed/36795625 http://dx.doi.org/10.15585/mmwr.mm7207a3 Text en https://creativecommons.org/publicdomain/zero/1.0/All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated. |
| spellingShingle | Full Report Fleming-Dutra, Katherine E. Ciesla, Allison Avrich Roper, Lauren E. Smith, Zachary R. Miller, Joseph D. Accorsi, Emma K. Verani, Jennifer R. Shang, Nong Derado, Gordana Wiegand, Ryan E. Pilishvili, Tamara Britton, Amadea Link-Gelles, Ruth Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 |
| title | Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 |
| title_full | Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 |
| title_fullStr | Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 |
| title_full_unstemmed | Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 |
| title_short | Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 |
| title_sort | preliminary estimates of effectiveness of monovalent mrna vaccines in preventing symptomatic sars-cov-2 infection among children aged 3–5 years — increasing community access to testing program, united states, july 2022–february 2023 |
| topic | Full Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949847/ https://www.ncbi.nlm.nih.gov/pubmed/36795625 http://dx.doi.org/10.15585/mmwr.mm7207a3 |
| work_keys_str_mv | AT flemingdutrakatherinee preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 AT cieslaallisonavrich preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 AT roperlaurene preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 AT smithzacharyr preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 AT millerjosephd preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 AT accorsiemmak preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 AT veranijenniferr preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 AT shangnong preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 AT deradogordana preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 AT wiegandryane preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 AT pilishvilitamara preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 AT brittonamadea preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 AT linkgellesruth preliminaryestimatesofeffectivenessofmonovalentmrnavaccinesinpreventingsymptomaticsarscov2infectionamongchildrenaged35yearsincreasingcommunityaccesstotestingprogramunitedstatesjuly2022february2023 |